Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06601231 | To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.(ADRENALIN) | recruiting | — | 1,000 | Erasmus Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602986 | Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma | not yet recruiting | N/A | 96 | Pak Emirates Military HospitalOTHER |
| 1 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT06581315 | Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma | recruiting | N/A | 204 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04498767 | Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)(OligoRARE) | recruiting | N/A | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Aug 26, 2024 | clinicaltrials |
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06434493 | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma(EMPHATIC) | not yet recruiting | N/A | 30 | The Christie NHS Foundation TrustOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06563934 | Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs) | not yet recruiting | Phase 2 | 70 | Xu Yong, MDOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06561399 | Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) | recruiting | — | 28 | Fujian Provincial HospitalOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06559761 | Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research | recruiting | — | 500 | Chinese PLA General HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06557213 | a Cohort Study (Gut Microbiota and HCC) | not yet recruiting | — | 100 | Xu Yong, MDOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT05404347 | NGS in Gallbladder Cancer and Response to Treatment | recruiting | — | 100 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06550921 | Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma | recruiting | N/A | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06519578 | Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 1,115 | RenJi HospitalOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06538935 | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06536998 | Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver） | recruiting | — | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06535737 | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab(CPAB) | not yet recruiting | Phase 2 | 40 | Chulalongkorn UniversityOTHER | 0 | Aug 2, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06524466 | Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06512467 | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06502080 | Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)(RADITOP) | not yet recruiting | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De ToniOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06341270 | Efficacy of TEAS on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy | recruiting | N/A | 524 | West China HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06490107 | Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | not yet recruiting | Phase 1 | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06138769 | Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma | active not recruiting | Phase 2 | 50 | Asan Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482801 | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478927 | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib | recruiting | N/A | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03949231 | Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma | recruiting | Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06470256 | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Zhiyong HuangOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06449846 | Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 152 | Zhujiang HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02920554 | The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer | recruiting | N/A | 88 | Saint Vincent's Hospital, KoreaOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06204835 | ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery | recruiting | Phase 1 | 90 | Institute of Automation, Chinese Academy of SciencesOTHER | 1 | May 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials